Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
CELZ•Trial enrollment and treatment completed
Creative Medical Technology Holdings Inc. CELZ.O said it has successfully completed enrollment and treatment across the entire FDA-cleared Adapt trial, including the opioid cohort.
The company said the completion advances Celz-201 / Olastrocel toward RMAT evaluation and Phase 3 planning.
